

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 January 2023 (19.01.2023)



(10) International Publication Number
WO 2023/288289 A2

- (51) **International Patent Classification:**
Not classified
- (21) **International Application Number:**
PCT/US2022/073754
- (22) **International Filing Date:**
14 July 2022 (14.07.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/221,568 14 July 2021 (14.07.2021) US
- (71) **Applicant: MIRECULE, INC.** [US/US]; 704 Quince Orchard Road, Suite 140, Gaithersburg, MD 20878 (US).
- (72) **Inventors: SALEH, Anthony;** c/o miRecule, Inc., 704 Quince Orchard Road, Suite 140, Gaithersburg, MD 20878 (US). **BELGARD, Grant;** 7376 Bella Foresta Place, Sanford, FL 32771 (US). **MUNZ, Marton;** c/ Ventalló 75, P02 PTA1, Barcelona, Barcelona (ES). **MARUSAK, Charles;**

c/o miRecule, Inc., 704 Quince Orchard Road, Gaithersburg, MD 20878 (US). **PLACE, Robert;** c/o miRecule, Inc., 704 Quince Orchard Road, Suite 140, Gaithersburg, MD 20878 (US).

(74) **Agent: BROWNING, Matthew et al.;** c/o Greenberg Traurig, LLP, 1000 Louisiana Street, Suite 1700, Houston, TX 77002 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) **Title:** OLIGONUCLEOTIDES AND COMPOSITIONS THEREOF FOR NEUROMUSCULAR DISORDERS




FIG. 1

(57) **Abstract:** Disclosed herein are engineered DUX4-targeting oligonucleotides for selective inhibition of RNA transcripts associated with a neuromuscular disease such as facioscapulohumeral muscular dystrophy. Also disclosed are vectors containing any of these, pharmaceutical formulations containing any of the these, and kits containing any of the these. Also disclosed herein are methods of selectively inhibiting polypeptide expression and activity by contacting a DUX4-targeting oligonucleotide with an RNA transcript associated with a neuromuscular disease such as facioscapulohumeral muscular dystrophy.

[Continued on next page]

WO 2023/288289 A2

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*